The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma

A young man with alveolar soft part sarcoma and his identical twin were studied in terms of immunologic response to the patient's tumor homogenate. The lymphocytes from both twins underwent lymphoblastic transformation to tumor homogenate but only the healthy twin's lymphocytes released demonstrable migration inhibition factor (MIF) to the tumor preparation. Transfer factor was prepared from the healthy twin and administered to the tumor-bearing twin. A total dose of transfer factor equivalent to 45 × 10⁸ lymphocytes given in three separate doses produced a persistently positive MIF assay in the patient. The tumor neither regressed nor progressed during the 6-month period after transfer factor therapy.